Hadassah

New Research at Hadassah: Computational Tools Unravel the Mystery of Transient Amnesia

Tuesday, Dec 16 2014

Hadassah Medical Organization researchers have identified what happens physiologically during transient global amnesia (TGA), an episodic, rapid-onset amnesia that is characterized by a person’s impaired ability to retrieve and create newer memories, along with temporal disorientation and repetitive questioning that lasts up to 24 hours. The study findings were published in the May issue of the prestigious journal, Annals of Neurology (Volume 75, pages 634-643) and highlighted on the cover.

Although the occurrence of TGA has been known for more than 50 years, despite extensive research, it has been among the most enigmatic phenomena in neurology. There has been no clear evidence for its underlying pathophysiological basis and no imaging that could evaluate TGA in real time. Hadassah’s researchers, however, were able to record brain function of 12 TGA patients, using resting-state functional magnetic resonance imaging (RSfMRI) and conduct connectivity and cluster analyses to detect changes in the episodic memory network during TGA.

During a TGA attack, patients are alert and communicative and know who they are. However, their memory is significantly impaired, their disorientation in time is severe, and they engage in repeated questioning about their situation. The Hadassah study results revealed that functional connectivity within the episodic memory network was disturbed bilaterally most severely during the hyper-acute phase of TGA. The connectivity disturbances were specific to the episodic memory network, as no other network was disturbed. Consequently, the method developed in this study may serve for diagnosis of amnesia in real time.

“Our Computational Neuropsychiatry Laboratory,” says Hadassah Neurology Researcher Dr. Shahar Arzy, “is unique as it brings together highest level students and researchers with a strong background in computer science and physics, who work directly on patients’ data to better understand neuropsychiatric disorder and develop tools that facilitate diagnosis, monitoring, and treatment. Michael Peer, the PhD student who performed the current work and is a winner of the prestigious Eshkol Stipend, is an excellent example, combining highest computational ability, neuroscientific insight, and clinical dedication. The combination at Hadassah of an excellent and devoted neuroradiology team and the unique ability to apply cutting-edge science within the clinic is a precious winning situation.”

“Dr. Arzy, lead researcher of this study, is a specialist at Hadassah’s Neuropsychiatric Clinic and Epilepsy Center, as well as Director of the Computational Neuropsychiatric Laboratory at the Hadassah-Hebrew University Faculty of Medicine. Putting the research in broader perspective, he explains: “The notion of ‘brain centers’ that govern cognitive activity does not hold anymore, since we now understand the brain as a network of computational units, somewhat similar to the Internet. Neuropsychiatric disorders may emerge out of a disturbance in the coherent network activity. Likewise, our results are not only important for amnesia, but the work will be carried on to better understand and further treat other network-related neuropsychiatric disorders such as Alzheimer’s disease, dissociation, and depression. The unique combination of clinics and science at Hadassah and the brilliant team at our lab will surely make this possible.”

Comments

Related Stories

alt_text

Wednesday, Aug 16 2017

Gazan Boy Walks for First Time at Hadassah

Unable to stand on his feet, suffering from severe respiratory distress, a four-year-old boy from Gaza gained the ability to walk once Hadassah Hospital surgeons identified and removed a large tumor lodged in his chest.

READ MORE ›
alt_text

Wednesday, Aug 16 2017

Hadassah Hosts Health Innovation Conference

Over one hundred doctors, researchers, and entrepreneurs gathered at Hadassah Hospital Ein Kerem this summer to discuss how to advance the quality of patient care with computational power.

READ MORE ›
alt_text

Monday, Aug 14 2017

Hadassah Hosts First Human Trial with Drug to Fight Nasty Bacterial Infection

Immuron, an Australian biopharmaceutical company, has received approval from the Hadassah Medical Organization’s ethics committee and Israel’s Ministry of Health to begin its first clinical trial with a new drug to fight a bacterial infection called Clostridium Difficile (CDI).

READ MORE ›
alt_text

Thursday, Aug 3 2017

Mystery of Devastating Pediatric Disease Solved by Hadassah Team

A genetic mutation causing a rare and devastating pediatric neurological disease that has puzzled medical centers around the world has been identified at the Hadassah Medical Organization by Prof. Orly Elpeleg, head of Hadassah's Department of Genetics and Metabolic Diseases.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More